GlassScriptPhysician profile
Lindsey Mae Everline
NPI 1972016038
$5,559.53
in general payments reported to CMS, 2019-2025
30 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,191 · 2022: $1,225 · 2023: $1,558 · 2024: $1,360 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,069 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,068.68 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $725.65 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $571.73 | 2021-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $524.19 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Abbvie INC. | $416.99 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $371.07 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Mylan Specialty L.P. | $320.85 | 2021-2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $318.79 | 2022-2025 | Caplyta |
| Pfizer INC. | $304.11 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.24 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Biohaven Pharmaceutical Holding Company LTD. | $200.86 | 2022 | |
| Lundbeck LLC | $180.15 | 2023-2024 | Rexulti |
| Dexcom, INC. | $150.22 | 2022-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $142.87 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $135.27 | 2021-2023 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $133.69 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $131.42 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $114.41 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $90.14 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $79.20 | 2021 | |
| Axsome Therapeutics, INC. | $72.91 | 2023 | Auvelity |
| Merck Sharp & Dohme LLC | $60.69 | 2021 | |
| Vanda Pharmaceuticals INC. | $51.34 | 2024-2025 | Fanapt |
| Novartis Pharmaceuticals Corporation | $45.99 | 2022-2023 | |
| Abbott Laboratories | $44.17 | 2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $41.78 | 2021 | |
| Insulet Corporation | $19.79 | 2023 | Omnipod |
| Amgen INC. | $18.84 | 2022 | |
| Ironshore Pharmaceuticals INC. | $17.76 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.38 | 2021 | |
| Phadia US INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Everline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.